Advanced Glycation End Products and Inflammation in Type 1 Diabetes Development

Cells. 2022 Nov 4;11(21):3503. doi: 10.3390/cells11213503.

Abstract

Type 1 diabetes (T1D) is an autoimmune disease in which the β-cells of the pancreas are attacked by the host's immune system, ultimately resulting in hyperglycemia. It is a complex multifactorial disease postulated to result from a combination of genetic and environmental factors. In parallel with increasing prevalence of T1D in genetically stable populations, highlighting an environmental component, consumption of advanced glycation end products (AGEs) commonly found in in Western diets has increased significantly over the past decades. AGEs can bind to cell surface receptors including the receptor for advanced glycation end products (RAGE). RAGE has proinflammatory roles including in host-pathogen defense, thereby influencing immune cell behavior and can activate and cause proliferation of immune cells such as islet infiltrating CD8+ and CD4+ T cells and suppress the activity of T regulatory cells, contributing to β-cell injury and hyperglycemia. Insights from studies of individuals at risk of T1D have demonstrated that progression to symptomatic onset and diagnosis can vary, ranging from months to years, providing a window of opportunity for prevention strategies. Interaction between AGEs and RAGE is believed to be a major environmental risk factor for T1D and targeting the AGE-RAGE axis may act as a potential therapeutic strategy for T1D prevention.

Keywords: RAGE; autoimmunity; dietary AGEs; type 1 diabetes.

Publication types

  • Review
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Diabetes Mellitus, Type 1*
  • Glycation End Products, Advanced / metabolism
  • Humans
  • Hyperglycemia* / complications
  • Inflammation / complications
  • Receptor for Advanced Glycation End Products / metabolism

Substances

  • Glycation End Products, Advanced
  • Receptor for Advanced Glycation End Products

Grants and funding

A.K.F. is supported by a UQ Research Support Fellowship. J.M.F. is supported by a Leadership Award from the National health and Medical Research Council of Australia (GNT 2010053). This work was also supported by Mater Foundation.